S&P 500 Futures
(-0.08%) 5 304.25 points
Dow J Futures
(-0.09%) 40 140 points
Nasdaq Futures
(-0.05%) 18 465 points
Oil
(-0.07%) $83.11
Gas
(-0.62%) $1.752
Gold
(0.73%) $2 254.80
Silver
(0.74%) $25.10
Platinum
(0.21%) $923.00
USD/EUR
(0.16%) $0.928
USD/NOK
(0.20%) $10.86
USD/GBP
(0.00%) $0.792
USD/RUB
(0.01%) $92.59

Realtime updates for Atara Biotherapeutics Inc [ATRA]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
BUY
50.00%
return -17.81%
SELL
33.33%
return 17.99%
Last Updated28 Mar 2024 @ 16:00

-0.86% $ 0.694

BUY 62549 min ago

@ $0.771

Issued: 14 Feb 2024 @ 13:55


Return: -10.00%


Previous signal: Feb 13 - 15:34


Previous signal: Sell


Return: -0.05 %

Live Chart Being Loaded With Signals

Commentary (28 Mar 2024 @ 16:00):

Warning: Trying to access array offset on null in /home/getagraph/public_html/stock.php on line 302

Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States...

Stats
Today's Volume 1.19M
Average Volume 3.19M
Market Cap 89.66M
EPS $0 ( 2024-03-27 )
Next earnings date ( $-0.480 ) 2024-05-06
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -0.250
ATR14 $0.00400 (0.56%)
Insider Trading
Date Person Action Amount type
2024-03-04 Touchon Pascal Sell 24 844 Common Stock
2024-03-04 Nguyen Anhco Sell 10 746 Common Stock
2024-03-04 Murugan Amar Sell 10 044 Common Stock
2024-03-04 Hyllengren Eric J Sell 1 462 Common Stock
2024-03-04 Hyllengren Eric J Sell 5 217 Common Stock
INSIDER POWER
66.03
Last 100 transactions
Buy: 7 600 944 | Sell: 2 114 657

Volume Correlation

Long: 0.06 (neutral)
Short: 0.52 (weak)
Signal:(70.232) Neutral

Atara Biotherapeutics Inc Correlation

10 Most Positive Correlations
SRTS0.965
CDXS0.964
LGHL0.959
ZD0.957
ZYNE0.952
RKDA0.95
ATER0.949
HNNA0.948
NMTR0.948
DYNT0.946
10 Most Negative Correlations
MCAA-0.951
MSDA-0.949
CITE-0.945
DHAC-0.944
AHRN-0.942
LEGA-0.942
ADAL-0.942
FTAA-0.94
PFTA-0.939
ZING-0.939

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Atara Biotherapeutics Inc Correlation - Currency/Commodity

The country flag 0.00
( neutral )
The country flag -0.42
( neutral )
The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag 0.42
( neutral )

Atara Biotherapeutics Inc Financials

Annual 2022
Revenue: $63.57M
Gross Profit: $49.01M (77.08 %)
EPS: $-2.24
Q3 2023
Revenue: $2.14M
Gross Profit: $-477 000 (-22.31 %)
EPS: $-0.660
Q2 2023
Revenue: $957 000
Gross Profit: $-1.94M (-202.51 %)
EPS: $-0.680
Q1 2023
Revenue: $1.23M
Gross Profit: $1.01M (82.38 %)
EPS: $-0.720

Financial Reports:

No articles found.

Atara Biotherapeutics Inc

Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators